MRI predictors of clinically definite MS based on analyses of placebo patients from the CHAMPS trial

被引：0
|
作者：
Simon, JH
机构：
来源：
NEUROLOGY | 2002年 / 58卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A502 / A503
页数：2
相关论文
共 50 条
  • [41] Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial (vol 374, pg 1503, 2009)
    Comi, G.
    Martinelli, V
    Rodegher, M.
    LANCET, 2010, 375 (9724): : 1436 - 1436
  • [42] Early MRI predictors of clinical progression over 48 months in patients with clinically isolated syndrome
    Uher, T.
    Horakova, D.
    Kalincik, T.
    Bergsland, N.
    Tyblova, M.
    Ramasamy, D. P.
    Seidl, Z.
    Vaneckova, M.
    Krasensky, J.
    Havrdova, E.
    Zivadinov, R.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 404 - 405
  • [43] Treatment responses, disability outcomes and prognosis of a cohort of Sri Lankan patients with clinically definite multiple sclerosis: Preliminary data from a dedicated MS clinic
    Senanayake, B.
    Aravinthan, M.
    Rajapakshe, I.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [44] MRI enhancing lesion frequency from patients with MS enrolled in the placebo arms of clinical trials or in natural history studies
    Sormani, MP
    Molyneux, PD
    Barkhof, F
    Miller, DH
    Filippi, M
    MAGNETIC RESONANCE IMAGING, 1999, 17 (08) : 1236 - 1237
  • [45] Regression to the Mean and Predictors of MRI Disease Activity in RRMS Placebo Cohorts - Is There a Place for Baseline-to-Treatment Studies in MS?
    Stellmann, Jan-Patrick
    Stuerner, Klarissa Hanja
    Young, Kim Lea
    Siemonsen, Susanne
    Friede, Tim
    Heesen, Christoph
    PLOS ONE, 2015, 10 (02):
  • [46] Correlation between MRI Measures and Conversion to Clinically Definite Multiple Sclerosis in Patients Treated with Intramuscular Interferon Beta-1a
    Horakova, Dana
    Kalincik, Tomas
    Tyblova, Michaela
    Krasensky, Jan
    Vaneckova, Manuela
    Seidl, Zdenek
    You, Xiaojun
    Havrdova, Eva
    NEUROLOGY, 2012, 78
  • [47] More MS Patients Remain Free from Disease Activity with Teriflunomide Versus Placebo in TEMSO, a Phase III Trial
    Kremenchutzky, Marcelo
    O'Connor, Paul W.
    Wolinsky, Jerry
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Olsson, Tomas P.
    Truffinet, Philippe
    Dukovic, Deborah
    Miller, Aaron
    ANNALS OF NEUROLOGY, 2012, 72 : S72 - S72
  • [48] PREDICTORS OF HOSPITALIZATIONS: EXPLORATORY ANALYSES FROM THE LIFE STUDY RANDOMIZED CONTROLLED TRIAL
    Marsh, A.
    Miller, M. E.
    Guralnik, J.
    King, A. C.
    McDermott, M. M.
    GERONTOLOGIST, 2015, 55 : 560 - 560
  • [49] Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS
    Bommarito, Giulia
    Bellini, Alessandro
    Pardini, Matteo
    Solaro, Claudio
    Roccatagliata, Luca
    Laroni, Alice
    Capello, Elisabetta
    Mancardi, Giovanni Luigi
    Uccelli, Antonio
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (05) : 623 - 631
  • [50] Silent mri progression in ms patients during clinically stable pregnancy and post-partum period
    Rosciszewska-Zukowska, I.
    Siger, M.
    Stasiolek, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 657 - 657
12345